{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-329520","form_type":"8-K","ticker":"INDV","cik":"0001625297","company_name":"Indivior Pharmaceuticals, Inc.","filed_at":"2026-08-03T10:50:04+00:00","discovered_at":"2026-08-03T10:55:00.780411+00:00","generated_at":"2026-08-03T10:55:11.077638+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Indivior Q2 revenue $343M (+14% YoY), raises FY2026 guidance; merger with Supernus expected Q4","bullets":["Q2 GAAP net income $122M ($0.98 diluted EPS) vs $18M ($0.14) YoY; Non-GAAP net income $142M ($1.15).","Record SUBLOCADE net revenue $253M (+21% YoY); new patient starts of 32,816 were a record.","FY2026 guidance raised: total net revenue $1,295M-$1,365M; adjusted EBITDA $700M-$740M (midpoint +68% YoY).","Repurchased 4.7M shares for $175M in Q2; year-to-date $300M in buybacks.","Announced all-stock merger of equals with Supernus; expected close in Q4 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-329520","json":"https://secwatch.observer/filing/0001193125-26-329520.json","markdown":"https://secwatch.observer/filing/0001193125-26-329520.md","text":"https://secwatch.observer/filing/0001193125-26-329520.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1625297/000119312526329520/0001193125-26-329520-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1625297/000119312526329520/d118566d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-08-03T10:55:11.077638+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}